Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Shandong Luye Pharmaceutical
Shandong Luye Pharmaceutical
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Rykindo
Risperidone
2023-01-13
2025-2033
Dementia
,
Tourette syndrome
,
Schizophrenia
,
Bipolar disorder
,
Autistic disorder
,
Schizophrenia spectrum and other psychotic disorders
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Toludesvenlafaxine
depression
,
major depressive disorder
,
depressive disorder
Glycididazole
carcinoma
,
esophageal neoplasms
,
squamous cell carcinoma
Taxane
renal cell carcinoma
,
colorectal neoplasms
,
esophageal squamous cell carcinoma
,
anaplastic thyroid carcinoma
,
disease progression
,
hematologic neoplasms
,
neoplasms
,
pancreatic neoplasms
,
pancreatic ductal carcinoma
,
head and neck neoplasms
,
castration-resistant prostatic neoplasms
,
squamous cell carcinoma
,
adenocarcinoma
,
stomach neoplasms
,
urologic neoplasms
,
transitional cell carcinoma
,
sarcoma
,
recurrence
,
squamous cell carcinoma of head and neck
,
invasive hydatidiform mole
,
melanoma
,
urinary bladder neoplasms
,
hemangiosarcoma
,
squamous cell neoplasms
,
breast neoplasms
,
prostatic neoplasms
,
non-small-cell lung carcinoma
,
neoplasm metastasis
,
ovarian neoplasms
,
carcinoma
,
triple negative breast neoplasms
,
adenocarcinoma of lung
,
brain neoplasms
,
osteitis deformans
,
hereditary sensory and autonomic neuropathies
,
fallopian tube neoplasms
,
peritoneal neoplasms
,
lobular carcinoma
,
ductal carcinoma breast
,
lung neoplasms
,
neuroendocrine tumors
,
large cell carcinoma
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use